Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

This research study is evaluating a drug called buparlisib (BKM120) as a possible treatment for locally advanced head and neck squamous cell cancer.

Phase 1

Dana-Farber Cancer Institute

Novartis Pharmaceuticals

Cisplatin